T1	Participants 12 164	patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin
T2	Participants 388 432	patients with metastatic breast cancer (MBC)
T3	Participants 1800 1812	MBC patients
